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The	 imperative	 necessity	 of	 polypeptides	 to	 obtain	 their	 proper	










































2  | MATERIAL S AND METHODS
2.1 | Cell lines and cell culture conditions
The	 human	MM	 cell	 lines	 JJN3	 and	 RPMI	 8226	were	 kindly	 pro‐
vided	by	Prof.	C.	Mitsiades	(Dana‐Farber	Cancer	Institute,	Harvard	




BTZ	 (PS‐341)	 was	 from	 Calbiochem	 and	 EPOX	 from	 Enzo	 Life	
Sciences.	BTZ	and	EPOX	were	diluted	in	distilled	water	and	DMSO,	





2.3 | MAPK, STAT and MTH1 inhibitors
The	 MAPK	 inhibitors	 CI‐1040	 (against	 MEK	 1/2)	 and	 JNK‐IN‐8	
(against	 JNK	 1/2/3)	 were	 obtained	 from	 Cayman	 Chemical	 and	
Sigma‐Aldrich,	respectively.	The	MTH1	inhibitor	TH588	was	a	kind	




2.4 | Cell viability and measurement of proteasome 
peptidase activities
The	 cytotoxic	 effect	 of	 PIs	 against	 the	 MM	 cell	 lines	 was	 deter‐
mined	by	using	 the	MTT	 reagent	 (Sigma‐Aldrich).	The	proteasome	
activities	were	measured	as	described	before.18	For	details,	see	also	
Supporting	Information.
2.5 | Cell treatment with PIs and measurement of 
phosphorylated proteins and secreted cytokines/
chemokines using xMAP technology
Cells	 were	 plated	 in	 flat‐bottomed	 12‐well	 plates	 at	 a	 concentra‐
tion	of	500	000	cells/mL	in	the	presence	(or	not)	of	PIs,	and	plates	
were	transferred	in	a	humidified	incubator	(37°C);	24‐48	hours	later,	
the	 samples	 corresponding	 to	day	1	 and	day	2	of	 treatment	were	











lysis	 buffer	 supplemented	 with	 protease	 and	 phosphatase	 inhib‐
itors.	 Lysates	were	 centrifuged	 at	 13	 300	 g	 (4°C),	 and	 the	 super‐
natants	were	used	to	determine	protein	concentration	by	Bradford	
assay;	samples	were	stored	at	−80°C	until	the	acquisition	of	all	time‐
points.	 For	 the	 implementation	 of	 the	 bead‐based	 sandwich	 en‐
zyme‐linked	immunosorbent	assay	(ELISA)	protocol,	50	μL	of	xMAP	














analysis	 was	 performed	 by	 using	 the	 MS	 Excel	 and	 the	 Statistical	
Package	for	Social	Sciences	(IBM	SPSS;	version	19.0	for	Windows);	sig‐
nificance	was	evaluated	using	one‐way	analysis	of	variance	(ANOVA).	
Error	bars	indicate	standard	deviation	(SD);	significance	at	P < .05 or 
P	<	 .01	 is	 indicated	 in	graphs	or	heatmaps	by	one	or	 two	asterisks,	






3.1 | BTZ and EPOX induce cell death and suppress 


















cells,	 whereas	 EPOX	was	more	 selective	 for	 CT‐L	 activity	 (Figure	




3.2 | Among PIs that are highly selective for specific 
proteasomal peptidases, only Rub999 was partially 




















accordingly,	 selective	 inhibition	of	 the	β5	peptidase	by	Rub999	 in‐
creased	cell	death,	yet,	as	mentioned	 less	effectively	and	at	higher	
concentrations	as	compared	to	BTZ	or	EPOX,	and	likely	CFZ.22
3.3 | Proteasome inhibition at non‐lethal doses 
in MM cells modifies cell signalling in an inhibitor‐, 
time‐ and cell type‐specific manner; it also induces 
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the	therapeutic	intervention	in	the	clinic.23	Yet,	herein	we	aimed	to	
avoid	extensive	tumour	cell	death	in	order	to	investigate	the	effects	






S2C,D.	 Thus,	 the	 measured	 output	 mostly	 relates	 to	 proteasome	



























BTZ	 exerted	 minor	 alterations	 (except	 for	 STAT6	 increased	 phos‐
phorylation	at	day	2),	while	EPOX	caused	increased	phosphorylation	









































day	 2.	Our	 findings	 for	 phospho‐STAT3	 and	 phospho‐STAT6	were	
largely	verified	by	immunoblotting	analyses	in	JJN3	and	RPMI	8226	
cell	lysates	following	treatment	with	the	studied	PIs	(Figure	1A2,B2).
3.4 | Combined treatment of MM cells with PIs and 
a MTH1 inhibitor induced synergistic effects, whereas 
co‐treatment of MM cells with PIs and STAT3, 




oxidized	 nucleotides	 preventing	 thus	 their	 incorporation	 into	 the	
DNA.26	Exposure	of	MM	cells	to	TH588	showed	that	these	cell	lines	




Next,	 we	 examined	 whether	 co‐treatment	 of	 MM	 cells	 with	


















3.5 | Inhibition of proteasome at non‐lethal 
doses in MM cells results in the secretion of pro‐
tumorigenic and/or immunosuppressive cytokines/
chemokines
For	 these	 analyses	 by	 the	 LUMINEX	 platform,	 we	 used	 a	 panel	
of	 28	 cytokines/chemokines	 (Table	 S2).	 As	 for	 phosphoproteins,	
treatment	 of	 MM	 cells	 with	 non‐lethal	 doses	 of	 the	 PIs	 caused	
significant	 alterations	 in	 the	 secretion	 profile	 of	 the	 assayed	 cy‐
tokines/chemokines	 (Figure	3);	data	were	also	 tested	 for	 their	sig‐
nificance	(asterisks	in	Figure	3A1,B1),	plotted	on	bar	graphs	(Figure	
S9)	and	used	for	HCL	analyses	(Figure	S10).	In	JJN3	cells,	both	BTZ	
and	 EPOX	 caused	 (in	most	 cases)	 a	 gradual	 increase	 in	 cytokine/
chemokine	 secretion	 up	 to	 day	 7;	 yet,	 both	 PIs	 suppressed	 TNFA	
and	CXCL10	secretion.	Also,	BTZ	strongly	decreased	the	secretion	
of	 TNF12	 and	 IL1A;	 and	EPOX	of	 TNF10,	 IL3	 and	CCL3	 at	 day	7.	
Rub999	suppressed	 the	secretion	of	ZG16,	TNFA,	TNF12,	TNF10,	
IL6,	 IL20,	 IFNG,	 CXCL11,	 CXCL10	 and	 CCL5;	 Rub1024	 caused	 a	
mild	up‐regulation	in	the	secretion	of	most	analytes	assayed,	while	
























The	 use	 of	 therapeutic	 PIs	 represents	 a	 significant	 advance	 in	 the	
treatment	 of	 haematological	 malignancies,	 such	 as	MCL	 and	 espe‐
cially	MM.	 In	 fact,	achieving	complete	remission,	prolonging	overall	
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head‐to‐head	comparison	of	clinically	available	PIs	showed	that	in	the	
clinically	relevant	setting	only	the	co‐inhibition	of	C‐L	or	T‐L	with	CT‐L	





































exosomes	 establish	 a	 favourable	 bone	 marrow	 microenvironment	
which	 enhanced	 angiogenesis	 and	 immunosuppression	 through	 ac‐
tivation	 of	 the	 STAT3	 pathway,40	 as	well	 as	 that	 STAT3	 establishes	
an	 immunosuppressive	microenvironment	during	the	early	stages	of	





nosuppressive	 tumour	 microenvironment.43	 Furthermore,	 activated	









inhibition.	 Similarly,	 to	 alterations	 in	 cell	 signalling,	 these	 patterns	










lated	 apoptosis‐inducing	 ligand	 (TRAIL)‐armed	 exosomes	 deliver	
proapoptotic	signals	to	the	tumour	site,45	while	elotuzumab	enhances	
natural	killer	cell	activation	and	myeloma	cell	killing	through	IL2‐	and	

















against	 IL6,	 is	being	tested	 in	various	clinical	studies	along	with	PI	
treatment.52	IL6	levels	predict	event‐free	survival	in	paediatric	AML	







IL8	 is	 implicated	 in	 cancer	 cell	 growth,	 survival,	 angiogenesis	 and	
metastasis	 in	 several	 tumours.57	 In	 support,	 bone	marrow	 plasma	
and	stromal	cells	from	patients	with	MM	were	found	to	secret	higher	
amounts	of	IL8	than	healthy	donors;	additionally,	IL8	up‐regulation	
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